TY - JOUR
T1 - Maternal and Fetal Outcomes in an Observational Cohort of Women with Mycoplasma genitalium Infections
AU - Perin, Jamie
AU - Coleman, Jenell S.
AU - Ronda, Jocelyn
AU - Neibaur, Erica
AU - Gaydos, Charlotte A.
AU - Trent, Maria
N1 - Funding Information:
Conflict of Interest and Sources of Funding: This work was generously supported by an unrestricted grant from Hologic, Inc., to Johns Hopkins University and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD052459; principal investigator: M. Trent; funded: J. Ronda). Investigators M. Trent, J. Perin, and C.A. Gaydos were also supported by the National Institute of Nursing Research (5R01NR013507). Aside from this grant, Dr. Trent also receives research support through a material transfer agreement with SpeeDx, LLC, through Johns Hopkins University and serves on the Trojan Sexual Health Advisory Council (Church & Dwight, Inc.). Dr. Gaydos reports receiving research funding grants from Hologic and receiving speaker funding for educational lectures. The other coauthors declare that they have no competing interests.
Publisher Copyright:
© 2023 Lippincott Williams & Wilkins.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background Despite evidence that Mycoplasma genitalium (MG) is a risk factor for adverse outcomes in pregnancy, screening in pregnant women is not currently recommended. Methods Pregnant women between the ages of 13 and 29 years were recruited during their routine prenatal visits, screened for sexually transmitted infections (STIs) and followed for 1 year. We compared women with MG to those with no STIs, excluding women with STIs other than MG (Chlamydia trachomatis [CT], Neisseria gonorrhoeae [NG], or Trichomonas vaginalis [TV]) unless they were also codiagnosed with MG. Adverse outcomes were extracted from participants' medical records and compared between women with MG and those without STIs using exact or nonparametric approaches. Estimated differences were also adjusted for demographics using propensity scores with linear and logistic regression, where appropriate. We exclude women with MG and CT, NG, or TV diagnosis for primary analysis. Results Of 281 participants enrolled from September 2015 until July 2019, 51 (18.1%) were diagnosed with MG. Of 51 women with MG, 12 (24%) were also diagnosed with CT, NG, or TV. All women with MG were offered treatment with azithromycin; however, only 28 (55%) were documented to receive treatment. Women with MG had similar outcomes to those with no STIs with a few exceptions. Average birth weight was lower among women with MG alone compared with women with no STIs when excluding coinfections (169-g difference, 15-323). Conclusions Our results indicate that MG is common in pregnant women and often presents as a coinfection. More research using population-based designs is needed to determine whether screening or treatment for women at risk for low birth weight or coinfections is warranted.
AB - Background Despite evidence that Mycoplasma genitalium (MG) is a risk factor for adverse outcomes in pregnancy, screening in pregnant women is not currently recommended. Methods Pregnant women between the ages of 13 and 29 years were recruited during their routine prenatal visits, screened for sexually transmitted infections (STIs) and followed for 1 year. We compared women with MG to those with no STIs, excluding women with STIs other than MG (Chlamydia trachomatis [CT], Neisseria gonorrhoeae [NG], or Trichomonas vaginalis [TV]) unless they were also codiagnosed with MG. Adverse outcomes were extracted from participants' medical records and compared between women with MG and those without STIs using exact or nonparametric approaches. Estimated differences were also adjusted for demographics using propensity scores with linear and logistic regression, where appropriate. We exclude women with MG and CT, NG, or TV diagnosis for primary analysis. Results Of 281 participants enrolled from September 2015 until July 2019, 51 (18.1%) were diagnosed with MG. Of 51 women with MG, 12 (24%) were also diagnosed with CT, NG, or TV. All women with MG were offered treatment with azithromycin; however, only 28 (55%) were documented to receive treatment. Women with MG had similar outcomes to those with no STIs with a few exceptions. Average birth weight was lower among women with MG alone compared with women with no STIs when excluding coinfections (169-g difference, 15-323). Conclusions Our results indicate that MG is common in pregnant women and often presents as a coinfection. More research using population-based designs is needed to determine whether screening or treatment for women at risk for low birth weight or coinfections is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85121957685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121957685&partnerID=8YFLogxK
U2 - 10.1097/OLQ.0000000000001569
DO - 10.1097/OLQ.0000000000001569
M3 - Article
C2 - 34654767
AN - SCOPUS:85121957685
SN - 0148-5717
VL - 48
SP - 991
EP - 996
JO - Sexually transmitted diseases
JF - Sexually transmitted diseases
IS - 12
ER -